CoChat
Sign Up
Cited by 39Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesMental Health Treatment and Access

Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression

Shelton, Richard C., Andorn, Anne C., Mallinckrodt, Craig H., Wohlreich, Madelaine M., Raskin, Joel, Watkin, John G., Detke, Michael J.·2007·International Clinical Psychopharmacology
DOI 10.1097/yic.0b013e32821c6189
Open this paper in CoChat — free account

Abstract

Clinicians need to know whether duloxetine is effective in patients across a broad range of depressive symptoms and depression severity. Data were pooled from nine randomized, double-blind, placebo-controlled studies in major depressive disorder (total N=2227) comparing duloxetine (40-120 mg/day) with placebo for 8-9 weeks. Patients were retrospectively stratified by baseline score on the HAMD17 into mild (< or =19; n=682), moderate (n=1099), or severe (> or =25; n=446) groups. Duloxetine produced significantly greater baseline-to-endpoint mean change than placebo in HAMD17 total score, Maier and retardation subscales, and the Clinical Global Impressions-Severity of Illness scale in all three cohorts. Significant improvement was seen in HAMD17 items 1 (depressed mood), 3 (suicide), 7 (work and activities), and 10 (psychic anxiety) regardless of severity. The HAMD17 anxiety subscale and items 13 (somatic symptoms-general) and 15 (hypochondriasis) showed significant improvement only in moderately and severely ill patients. Significant improvement in the HAMD17 Maier subscale was seen in all groups by week 1. In all three groups, placebo was significantly superior to duloxetine at early visits on HAMD17 item 12 (somatic symptoms-GI). Mildly and severely ill patients exhibited significant reduction in visual analog scale overall pain severity at the study endpoint. The studies contained fewer patients with very mild or very severe illness, limiting our ability to draw conclusions in these patient populations. Duloxetine demonstrated superior efficacy in the treatment of major depressive disorder, when compared with placebo, regardless of the baseline severity of depressive symptoms, although effect sizes were largest in the most severely depressed patients.

Integrity signals

Registry

Crossref · 10.1097/yic.0b013e32821c6189

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The reporting of pain severity is partly determined by depression severity.

    “It has been documented that the reporting of pain severity is partly determined by depression severity (Shelton et al., 2007).”

    From Presence and predictors of pain in depression: Results from the FINDER study (2010) · cites this paper as Shelton et al., 2007

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Shelton, R. C., Andorn, A. C., Mallinckrodt, C. H., Wohlreich, M. M., Raskin, J., Watkin, J. G., & Detke, M. J.
Affiliations
  • Vanderbilt University (US)
  • Eli Lilly (United States) (US)
Corresponding author
Wohlreich, Madelaine M.
ORCID
Venue
International Clinical Psychopharmacology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2007-11
Volume
22
Issue
6
Pages
348-355
ISSN
0268-1315 (ISSN-L)
DOI
10.1097/yic.0b013e32821c6189
OpenAlex
W1977851413
Cited by
39
References
52
Citations by year
2023: 1 · 2021: 1 · 2019: 1 · 2018: 1 · 2016: 1 · 2014: 2 · 2013: 2 · 2012: 3
FWCI
0.59
Type
journal article
Language
en
Open access
closed
Locations
  • International Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • Pfizer Pharmaceuticals
  • Janssen Pharmaceuticals
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Social Sciences › Psychology › Social Psychology › Mental Health Treatment and Access
Keywords
duloxetine, major depressive disorder, depression severity, antidepressant efficacy, placebo comparison, Hamilton Depression Rating Scale, depressive symptoms, anxiety symptoms, somatic symptoms, pain intensity
MeSH terms
Duloxetine Hydrochloride, Adolescent, Adult, Aged, Aged, 80 and over, Antidepressive Agents, Major Depressive Disorder, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Retrospective Studies, Severity of Illness Index, Thiophenes, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Treatment Outcome, Diagnostic and Statistical Manual of Mental Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review